Short Interest in BrainsWay Ltd. (NASDAQ:BWAY) Declines By 31.0%

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 55,300 shares, a decline of 31.0% from the February 13th total of 80,200 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily trading volume, of 65,600 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a report on Wednesday.

BrainsWay Price Performance

Shares of BWAY stock opened at $10.21 on Friday. BrainsWay has a 12-month low of $4.61 and a 12-month high of $11.79. The firm has a fifty day moving average of $10.26 and a 200-day moving average of $9.62. The firm has a market capitalization of $192.22 million, a price-to-earnings ratio of 102.11 and a beta of 1.29.

Institutional Trading of BrainsWay

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its holdings in shares of BrainsWay by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after buying an additional 1,786 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after acquiring an additional 2,144 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in BrainsWay by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after acquiring an additional 2,446 shares during the last quarter. Lazard Asset Management LLC acquired a new position in BrainsWay during the 4th quarter worth about $44,000. Finally, JPMorgan Chase & Co. raised its stake in BrainsWay by 61.9% during the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after buying an additional 9,149 shares during the last quarter. 30.11% of the stock is owned by institutional investors.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.